Taysha Gene Therapies, Inc.
Taysha Gene Therapies Announces Regenerative Medicine Advanced Therapy (RMAT) Designation Granted by U.S. FDA for TSHA-102 in Rett Syndrome
May 2, 2024
Taysha announced the FDA has granted RMAT designation to TSHA-102. Companies receiving RMAT designation can benefit from increased interactions with the FDA with the goal of expediting drug development.